PV Watch Daily Blog
Fresh reporting, analysis, and expert insight on drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, and career trends.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FDA Requires Vitamin B6 Deficiency Warning for Carbidopa/Levodopa
FDA says it is requiring application holders for all drug products containing carbidopa/levodopa to add a warning that these medicines can cause vitamin B6...
Why Product Management Service and SPOR Literacy Can Strengthen a PV Career
EMA’s substance and product data management services guidance says marketing authorisation holders should verify that data submitted to XEVMPD or SIAMED...
What PRAC Safety Signals Mean for Pharmacovigilance Teams
For pharmacovigilance professionals working in or around the European regulatory environment, PRAC safety signals are among the most important routine outputs...
PAHO Calls for Stronger Pharmacovigilance After Reports of GLP-1 Misuse
The Pan American Health Organization has called for strengthened pharmacovigilance following reports of misuse involving GLP-1 medicines indicated for...
UK Clinical Trial Rules Change on 28 April 2026: What PV Teams Should Prepare For
The UK’s updated clinical trials regulations will come into force on 28 April 2026, marking an important date for sponsors, researchers, and pharmacovigilance...
FDA Launches AEMS: Why the New Adverse Event Monitoring System Matters for Pharmacovigilance
The U.S. Food and Drug Administration has launched the FDA Adverse Event Monitoring System (AEMS), a new unified platform designed to modernize how adverse...